Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center
| Autor: | Rebecca Jeun, Priyanka C Iyer, Conor Best, Victor Lavis, Jeena M Varghese, Sireesha Yedururi, Veronica Brady, Isabella C Glitza Oliva, Ramona Dadu, Denai R Milton, Kristy Brock, Sonali Thosani |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Immunotherapy. 15:417-428 |
| ISSN: | 1750-7448 1750-743X |
| DOI: | 10.2217/imt-2021-0316 |
| Popis: | Introduction: Immune checkpoint inhibitor-associated diabetes mellitus (ICI-DM) is a rare adverse event. In this study, we characterize clinical outcomes of patients with ICI-DM and evaluate survival impact of this complication on melanoma patients. Research design & methods: We conducted a retrospective review of 76 patients diagnosed with ICI-DM from April 2014 to December 2020. Results: 68% of patients presented in diabetic ketoacidosis, 16% had readmissions for hyperglycemia, and hypoglycemia occurred in 70% of patients after diagnosis. Development of ICI-DM did not impact overall survival or progression-free survival in melanoma patients. Conclusion: Development of ICI-DM is associated with long-term insulin dependence and pancreatic atrophy; the use of diabetes technology in this patient population can help improve glycemic control. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|